Invex Historical Income Statement

IXC Stock

0.07 0.01 7.46%

Historical analysis of Invex Therapeutics income statement accounts such as Interest Expense of 96.5 K or Selling General Administrative of 1.1 M can show how well Invex Therapeutics performed in making a profits. Evaluating Invex Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Invex Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Invex Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Invex Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Invex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Invex Income Statement Analysis

Invex Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Invex Therapeutics shareholders. The income statement also shows Invex investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Invex Therapeutics Income Statement Chart

At this time, Invex Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Total Revenue is likely to gain to about 1.3 M in 2024, whereas Net Loss is likely to drop (1.7 M) in 2024.

Tax Provision Selling General Administrative Selling And Marketing Expenses Total Revenue Gross Profit Net Income From Continuing Ops

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Total Revenue

Total revenue comprises all receipts Invex Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Invex Therapeutics minus its cost of goods sold. It is profit before Invex Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from Invex Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Invex Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Invex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2022	2023	2024 (projected)
Gross Profit	459.1K	1.2M	1.3M
Total Revenue	459.1K	1.2M	1.3M

Gross Profit Total Revenue

Invex Therapeutics income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Interest Income	Interest Income
Depreciation And Amortization		0.82	0.76	0.48	0.48	0.99	-0.99	-0.97	-0.95	0.99	-0.93	0.99	-0.99	0.16	-0.98	-0.9	0.76	0.76
Selling General Administrative	0.82		0.96	0.67	0.68	0.86	-0.81	-0.75	-0.67	0.76	-0.68	0.86	-0.87	-0.29	-0.8	-0.57	0.57	0.57
Selling And Marketing Expenses	0.76	0.96		0.6	0.61	0.81	-0.77	-0.72	-0.67	0.71	-0.67	0.81	-0.83	-0.26	-0.77	-0.58	0.49	0.49
Total Revenue	0.48	0.67	0.6		1.0	0.56	-0.38	-0.27	-0.28	0.51	-0.16	0.56	-0.5	-0.72	-0.32	-0.25	0.62	0.62
Gross Profit	0.48	0.68	0.61	1.0		0.56	-0.39	-0.27	-0.28	0.51	-0.16	0.56	-0.51	-0.72	-0.33	-0.25	0.61	0.61
Other Operating Expenses	0.99	0.86	0.81	0.56	0.56		-0.98	-0.95	-0.93	0.99	-0.9	1.0	-1.0	0.07	-0.96	-0.88	0.79	0.79
Operating Income	-0.99	-0.81	-0.77	-0.38	-0.39	-0.98		0.99	0.97	-0.97	0.97	-0.98	0.99	-0.25	1.0	0.92	-0.74	-0.74
Net Income From Continuing Ops	-0.97	-0.75	-0.72	-0.27	-0.27	-0.95	0.99		0.98	-0.95	0.99	-0.95	0.97	-0.35	1.0	0.93	-0.69	-0.69
Ebit	-0.95	-0.67	-0.67	-0.28	-0.28	-0.93	0.97	0.98		-0.96	0.98	-0.93	0.94	-0.4	0.97	0.98	-0.73	-0.73
Research Development	0.99	0.76	0.71	0.51	0.51	0.99	-0.97	-0.95	-0.96		-0.92	0.99	-0.98	0.18	-0.95	-0.93	0.83	0.83
Ebitda	-0.93	-0.68	-0.67	-0.16	-0.16	-0.9	0.97	0.99	0.98	-0.92		-0.9	0.93	-0.46	0.98	0.93	-0.64	-0.64
Total Operating Expenses	0.99	0.86	0.81	0.56	0.56	1.0	-0.98	-0.95	-0.93	0.99	-0.9		-1.0	0.07	-0.96	-0.88	0.79	0.79
Income Before Tax	-0.99	-0.87	-0.83	-0.5	-0.51	-1.0	0.99	0.97	0.94	-0.98	0.93	-1.0		-0.11	0.98	0.89	-0.76	-0.76
Total Other Income Expense Net	0.16	-0.29	-0.26	-0.72	-0.72	0.07	-0.25	-0.35	-0.4	0.18	-0.46	0.07	-0.11		-0.29	-0.45	0.06	0.06
Net Income	-0.98	-0.8	-0.77	-0.32	-0.33	-0.96	1.0	1.0	0.97	-0.95	0.98	-0.96	0.98	-0.29		0.91	-0.69	-0.69
Income Tax Expense	-0.9	-0.57	-0.58	-0.25	-0.25	-0.88	0.92	0.93	0.98	-0.93	0.93	-0.88	0.89	-0.45	0.91		-0.74	-0.74
Net Interest Income	0.76	0.57	0.49	0.62	0.61	0.79	-0.74	-0.69	-0.73	0.83	-0.64	0.79	-0.76	0.06	-0.69	-0.74		1.0
Interest Income	0.76	0.57	0.49	0.62	0.61	0.79	-0.74	-0.69	-0.73	0.83	-0.64	0.79	-0.76	0.06	-0.69	-0.74	1.0

Click cells to compare fundamentals

Invex Therapeutics Account Relationship Matchups

Invex Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	3.2M	2.4M	4.0M	8.5M	2.1M	3.8M
Selling General Administrative	1.4M	993.4K	900.4K	1.3M	1.2M	1.1M
Total Revenue	165.7K	158.8K	182.3K	459.1K	1.2M	1.3M
Other Operating Expenses	3.4M	2.4M	4.2M	9.0M	3.3M	4.2M
Operating Income	(3.3M)	(2.4M)	(4.0M)	(8.5M)	(2.1M)	(2.2M)
Net Income From Continuing Ops	(3.4M)	(2.3M)	(4.0M)	(7.7M)	(1.6M)	(1.7M)
Ebit	(3.3M)	(4.9M)	(8.3M)	(17.5M)	(2.9M)	(3.0M)
Research Development	1.6M	1.1M	3.0M	7.4M	2.0M	2.8M
Ebitda	(3.3M)	(2.4M)	(4.2M)	(9.0M)	(720.4K)	(756.5K)
Total Operating Expenses	3.4M	2.4M	4.2M	9.0M	3.3M	4.2M
Income Before Tax	(3.4M)	(2.3M)	(4.0M)	(7.7M)	(2.9M)	(3.0M)
Total Other Income Expense Net	(117.9K)	158.8K	79.9K	797.1K	(720.4K)	(684.4K)
Net Income Applicable To Common Shares	(3.4M)	(2.3M)	(4.0M)	(7.7M)	(7.0M)	(6.6M)
Net Income	(3.4M)	(2.3M)	(4.0M)	(7.7M)	(1.6M)	(1.7M)
Income Tax Expense	(47.8K)	(2.4M)	(4.1M)	(9.3M)	(1.2M)	(1.3M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Invex Stock Analysis

When running Invex Therapeutics' price analysis, check to measure Invex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invex Therapeutics is operating at the current time. Most of Invex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Invex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invex Therapeutics' price. Additionally, you may evaluate how the addition of Invex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC